EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: The Conundrum of What to Pick? Antibiotic Susceptibility Variability in Burkholderia cenocepacia in Cystic Fibrosis: Implications for Antibiotic Susceptibility Testing and Treatment

John E Moore, John McCaughan, Jacqueline C Rendall, Beverley C Millar

British Journal of Biomedical Science · 2024

DOI: 10.3389/bjbs.2024.12749 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Biomedical Science, 2024. Verfasst von John E Moore und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Disinfection and Pathogen Elimination Studies, Northern Ireland Public Health Laboratory, Belfast City Hospital, Belfast, Northern Ire…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Anti-Bacterial Agents, Microbial Sensitivity Tests, Burkholderia cenocepacia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Within cystic fibrosis microbiology, there is often mismatch between the antibiotic susceptibility result of an isolated bacterial pathogen and the clinical outcome, when the patient is treated with the same antibiotic. The reasoning for this remains largely elusive. Antibiotic susceptibility to four antibiotics (ceftazidime, meropenem, minocycline and trimethoprim-sulfamethoxazole) was determined in consecutive isolates ( n = 11) from an adult cystic fibrosis patient, over a 63 month period. Each isolate displayed its own unique resistotype. The first isolate was sensitive to all four antibiotics, in accordance with Clinical and Laboratory Standards Institute methodology and interpretative criteria. Resistance was first detected at four months, showing resistance to ceftazidime and meropenen and intermediate resistance to minocycline and trimethoprim-sulfamethoxazole. Pan resistance was first detected at 18 months (resistotype IV), with three resistotypes (I, II and III) preceding this complete resistotype. The bacterium continued to display further antibiotic susceptibility heterogeneity for the next 45 months, with the description of an additional seven resistotypes (resistotypes V–XI). The Relative Resistance Index of this bacterium over the 63 month period showed no relationship between the development of antibiotic resistance and time. Adoption of mathematical modelling employing multinomial distribution demonstrated that large numbers of individual colony picks (>40/sputum), would be required to be 78% confident of capturing all 11 resistotypes present. Such a requirement for large numbers of colony picks combined with antibiotic susceptibility-related methodological problems creates a conundrum in biomedical science practice, in providing a robust assay that will capture antibiotic susceptibility variation, be pragmatic and cost-effective to deliver as a pathology service, but have the reliability to help clinicians select appropriate antibiotics for their patients. This study represents an advance in biomedical science as it demonstrates potential variability in antibiotic susceptibility testing with Burkholderia cenocepacia . Respiratory physicians and paediatricians need to be made aware of such variation by biomedical scientists at the bench, so that clinicians can contextualise the significance of the reported susceptibility result, when selecting appropriate antibiotics for their cystic fibrosis patient. Furthermore, consideration needs to be given in providing additional guidance on the laboratory report to highlight this heterogeneity to emphasise the potential for misalignment between susceptibility result and clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAnti-Bacterial AgentsMicrobial Sensitivity TestsBurkholderia cenocepaciaBurkholderia InfectionsHumansAdultDrug Resistance, Bacterial

Stichwörter der Autor:innen

Burkholderia cenocepaciaCFantibiotic susceptibilityantibiotic treatmentbiomedical sciencecystic fibrosismicrobiology

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Laboratory for Disinfection and Pathogen Elimination Studies, Northern Ireland Public Health Laboratory, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom.
  • Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom.
  • Department of Medical Microbiology, The Royal Group of Hospitals, Belfast, Northern Ireland, United Kingdom.

Zitieren

APA

Moore, J. E., McCaughan, J., Rendall, J. C., & Millar, B. C. (2024). Case Report: The Conundrum of What to Pick? Antibiotic Susceptibility Variability in Burkholderia cenocepacia in Cystic Fibrosis: Implications for Antibiotic Susceptibility Testing and Treatment. British Journal of Biomedical Science. https://doi.org/10.3389/bjbs.2024.12749

Vancouver

Moore JE, McCaughan J, Rendall JC, Millar BC. Case Report: The Conundrum of What to Pick? Antibiotic Susceptibility Variability in Burkholderia cenocepacia in Cystic Fibrosis: Implications for Antibiotic Susceptibility Testing and Treatment. British Journal of Biomedical Science. 2024. doi:10.3389/bjbs.2024.12749

BibTeX
@article{Moore2024,
  author = {Moore, John E and McCaughan, John and Rendall, Jacqueline C and Millar, Beverley C},
  title = {Case Report: The Conundrum of What to Pick? Antibiotic Susceptibility Variability in Burkholderia cenocepacia in Cystic Fibrosis: Implications for Antibiotic Susceptibility Testing and Treatment},
  journal = {British Journal of Biomedical Science},
  year = {2024},
  doi = {10.3389/bjbs.2024.12749}
}
Kostenlos starten →